Return to CBI Antibody Core Home Page
  Return to biothreat/emerging pathogens list
    Return to Tuberculosis (Mtb strain H37Rv) ( Mycobacterium tuberculosis H37Rv ) list


Tuberculosis (Mtb strain H37Rv) ( Mycobacterium tuberculosis H37Rv )
Rv3314c



Western result: ++
GST
GST-Rv3314c
(fragment)

N.A. kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (GST-antigen fusion protein). The negative control lane is the same except it contains ~50ng to 100 ng of a GST fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used and it is fused to GST.

Antibody Name/Abbreviation: Rv3314c
CBI Antibody Core Code: 1Ab101

"Lot" Number: 1 Position: To be posted
% Identical Homology of Target to Mouse Protein: N.A.
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
To be posted






Sequence Name: Rv3314c
Full name:
UniGene Number: N.A.
Accession Number: MTV016.14
Source organism: Tuberculosis (Mtb strain H37Rv) ( Mycobacterium tuberculosis H37Rv )
Full length size (aa): To be posted
NCBI information page: click here

Sequence Notes: NC000952.1 (g)

Full length sequence:
MTDFAFDAPTVIRTKRDGGRLSDAAIDWVVKAYTDGRVADEQMSALLMAI
VWRGMDRGEIARWTAAMLASGARLDFTDLPLATVDKHSTGGVGDKITLPL
VPVVAACGGAVPQASGRGLGHTGGTLDKLESITGFTANLSNQRVREQLCD
VGAAIFAAGQLAPADAKLYALRDITGTVESLPLIASSIMSKKLAEGAGAL
VLDVKVGSGAFMRSPVQARELAHTMVELGAAHGVPTRALLTEMNCPLGRT
VGNALEVAEALEVLAGGGPPDVVELTLRLAGEMLELAGIHGRDPAQTLRD
GTAMDRFRRLVAAQGGDLSKPLPIGSHSETVTAGASGTMGDIDAMAVGLA
AWRLGAGRSRPGARVQHGAGVRIHRRPGEPVVVGEPLFTLYTNAPERFGA
ARAELAGGWSIRDSPPQVRPLIVDRIV





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.